Epoetin Delta: Efficacy in the Treatment of Anaemia in Cancer Patients Receiving Chemotherapy

Clinical Oncology

Volumn 20, Issue 9, 2008, Pages 705-713

  Krzakowski, M ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Anaemia; cancer; efficacy; epoetin delta; haemoglobin; safety

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CREATININE; FERROUS FUMARATE; HEMOGLOBIN; PLACEBO; PLATINUM COMPLEX; RECOMBINANT ERYTHROPOIETIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ANEMIA; ARTICLE; BACKACHE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERTENSION; HYPOCALCEMIA; INJECTION SITE PAIN; LEG THROMBOSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TACHYCARDIA; TREATMENT DURATION; TREMOR; VASODILATATION;

ANEMIA; ANTINEOPLASTIC AGENTS; DOUBLE-BLIND METHOD; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; SAFETY;

EID: 52749085332     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2008.06.001     Document Type: Article

References (28)

1. Ludwig H., Van Belle S., Barrett-Lee P., et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40 (2004) 2293-2306
2. Cunningham R.S. Anemia in the oncology patient: cognitive function and cancer. Cancer Nurs 26 (2003) 38S-42S
3. Barrett-Lee P.J., Ludwig H., Birgegard G., et al. Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey. Oncology 70 (2006) 34-48
4. Ross S.D., Allen I.E., Henry D.H., Seaman C., Sercus B., and Goodnough L.T. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther 28 (2006) 801-831
5. Seidenfeld J., Piper M., Flamm C., et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 93 (2001) 1204-1214
6. Leyland-Jones B., Semiglazov V., Pawlicki M., et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23 (2005) 5960-5972
7. Wright J.R., Ung Y.C., Julian J.A., et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25 (2007) 1027-1032
8. Henke M., Laszig R., Rube C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
9. Glaspy J, Smith R, Aapro M, et al. Results from a phase III, randomized, double-blind, placebo-controlled study of darbepoetin alfa for the treatment of anemia in patients not receiving chemotherapy or radiotherapy. American Association for Cancer Research Annual Meeting, 2007, Los Angeles.
10. Bohlius J., Wilson J., Seidenfeld J., et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 3 (2006) CD003407
11. European Medicines Agency. Epoetins and the risk of tumour growth progression and thromboembolic events in cancer patients and cardiovascular risks in patients with chronic kidney disease. Report no.: EMEA/494607/2007 (2007), European Medicines Agency, London
12. Spinowitz B.S., and Pratt R.D. Epoetin delta is effective for the management of anaemia associated with chronic kidney disease. Curr Med Res Opin 22 (2006) 2507-2513
13. Kwan J.T., and Pratt R.D. Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients. Curr Med Res Opin 23 (2007) 307-311
14. Martin K.J. Epoetin delta in the management of renal anaemia: results of a 6-month study. Nephrol Dial Transplant 22 (2007) 3052-3054
15. ®), in the management of anemia in patients with chronic kidney disease. Clin Nephrol 68 (2007) 26-31
16. Littlewood T.J., Nortier J., Rapoport B., et al. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy. Hematol Oncol 21 (2003) 169-180
17. Vansteenkiste J., Pirker R., Massuti B., et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94 (2002) 1211-1220
18. Crawford J., Cella D., Cleeland C.S., et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95 (2002) 888-895
19. Bellati F., Pernice M., Manci N., et al. Hemoglobin variation and blood transfusion rates in patients affected by locally advanced cervical cancer undergoing neo-adjuvant chemotherapy followed by radical surgery: the role of erythropoietic growth factors. Ann Oncol 18 (2007) 722-729
20. Abdelrazik N., and Fouda M. Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study. Hematology 12 (2007) 533-541
21. Hirsh V., Glaspy J., Mainwaring P., Manegold C., Ramlau R., and Eid J.E. Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy. Trials 8 (2007) 8
22. Savonije J.H., van Groeningen C.J., van Bochove A., et al. Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: results of a multicenter randomised controlled trial. Eur J Cancer 41 (2005) 1560-1569
23. Savonije J.H., van Groeningen C.J., Wormhoudt L.W., and Giaccone G. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level. Oncologist 11 (2006) 206-216
24. Granetto C., Ricci S., Martoni A., et al. Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy. Oncol Rep 10 (2003) 1289-1296
25. Estrin J.T., Schocket L., Kregenow R., and Henry D.H. A retrospective review of blood transfusions in cancer patients with anemia. Oncologist 4 (1999) 318-324
26. Hoffman-La Roche. Recruitment temporarily suspended into C.E.R.A. phase II oncology trial (23 February 2007), F. Hoffman-La Roche, Basel
27. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
28. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098